- Home
- EVH vs RIGL Comparison
EVH vs RIGL Comparison
Compare EVH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVH | RIGL |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.0M | 564.7M |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EVH | RIGL |
|---|---|---|
| Price | $4.24 | $49.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $7.93 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 3.1M | 291.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | ★ $907,957,000.00 | $294,282,000.00 |
| Revenue This Year | $33.89 | N/A |
| Revenue Next Year | $15.84 | $12.75 |
| P/E Ratio | ★ N/A | $35.98 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $2.10 | $24.84 |
| 52 Week High | $10.08 | $52.24 |
Technical Indicators
Market Signals| Indicator | EVH | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 71.60 |
| Support Level | $3.72 | $40.05 |
| Resistance Level | $4.54 | $52.24 |
| Average True Range (ATR) | 0.27 | 1.86 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 3.68 | 98.46 |
Price Performance
Historical ComparisonAbout EVH Evolent Health Inc
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.